There are a couple of Alzheimer's drugs that are due to receive...

There are a couple of Alzheimer's drugs that are due to receive market approval soon. They are showing efficacy, but some serious side-effects (brain bleeds and brain swelling). For this reason, patients require regular MRI scans for the first six months of treatment.
The need for regular MRI scans poses significant challenges. Access to MRI facilities for regular scans can be limited. Secondly, managing MRI scans for advanced Alzheimer's patients presents its own difficulties as patients often find it challenging to remain still for the duration required.
If the objective involves continuous monitoring for potential bleeding (such as haemorrhagic stroke) triggered by these drugs, leveraging technologies like EMV could prove pivotal. The market-entry of these drugs could potentially serve as an additional use case for EMV's EMU under its first regulatory clearance I would imagine?
This underscores the importance of exploring innovative solutions that align with regulatory approvals to enhance patient care and monitoring efficacy in challenging clinical scenarios.